bioihbjkbjnl/mcl2 huggingface dataset:
Prevalence of Subacromial Impingement Among Egyptian Swimmers
Condition: Subacromial Impingement Syndrome
MeSH terms: Shoulder Impingement Syndrome
Study type: Observational

Summary: 
      In the available literature, there are no prevalence studies that show the incidence of
      subacromial impingement in swimmers in Egypt, this should be considered as it's one of the
      most commonly reported injuries worldwide in swimmers. There are also no available studies to
      show the difference in incidence of subacromial impingement between both genders in Egypt.
      This study is attempting to remedy both research deficits and to reduce the literature gap
      and to show the prevalence rate of this injury among Egyptian swimmers in different age
      groups, to help prevent its widespread and to provide data for further investigations. This
      study would give the Egyptian swimming federation and the Ministry of youth and sports a
      clear idea about the prevalence rate of swimmer's shoulder at different ages in Egyptian
      swimmers. Most importantly, this study is to provide the physiotherapy community in Egypt
      data about this injury, the rate of prevalence and how to prevent it and hopefully would help
      in further future studies and also to apply it in different countries.
    


Intervention name(s): Handheld Dynamometer , Special tests and Modified DASH questionarre .
Intervention type(s): Other
Intervention description(s): A mix of tools , special tests and questionarre to help in confirming the diagnosis of subacromial impingement.
Other intervention name(s): Special tests ( Lift-off , Neers , Hawkins and kennedy tests); Modified DASH (Disabilities of the Arm, Shoulder, and Hand) questionarre .
Observational model: Other
Time perspective: Cross-Sectional
Sampling method: Non-Probability Sample
Study population: 
        Egyptian swimmers , Age ranging from 12 - 25 as mentioned in the subgroups and this study
        will be taken as a one shot.

        Swimmers will be collected from (Al-Ahly, Heliopolis, Shooting, El Shams, Al-zohour
        ,platinum , El-Nasr, Cairo ,Al-Maadi, Tala'ea Elgeish, Ittihad el shorta , El- Rowad
        ,Wadi-Degla, Shooting ,El Ghaba and El Geziera Sporting Clubs).
      
Keywords: Swimmers; Swimmer's shoulder; Subacromial impingement
Energy Requirements in Mitochondrial Disease
Condition: Mitochondrial Disease; Chronic Metabolic Disorder
MeSH terms: Metabolic Diseases; Mitochondrial Diseases
Study type: Observational

Summary: 
      Metabolic diseases and mitochondrial disorders are caused by genetic mutation which lead to
      disruptions in energy producing pathways in our body. Enough energy or calories must be given
      in the diet to ensure normal growth and development. Currently, energy needs for patients
      with metabolic and mitochondrial diseases are not measured, but is estimated using a
      mathematical equation based on healthy children. This may lead to under feeding or
      overfeeding of calories, and has negative nutritional implications.

      The clinical standard for measuring energy needs is the use of indirect calorimeter.The
      indirect calorimeter takes individualized measurements for each patient and therefore will
      enable dietitians and clinicians to provide sufficient calories in the diet to better manage
      the disease and promote normal growth and development.

      We believe daily energy requirements will vary within metabolic diseases (Phenylketonuria)
      and mitochondrial disorders (mitochondrial fatty acid oxidation defect, POLG1 mutation etc.).

      The objective of this preliminary study is to measure resting energy expenditure in children
      living with metabolic and mitochondrial conditions and data obtained will be used to generate
      future hypothesis and will form a basis for future studies.
    


Observational model: Case-Only
Time perspective: Cross-Sectional
Sampling method: Non-Probability Sample
Study population: 
        Children (1-18y) diagnosed with either phenylketonuria or a mitochondrial disorder
      
Keywords: POLG1 Mutation; Phenylketonuria
Mesenchymal Stem Cells to Treat Type 2 Diabetes
Condition: Type 2 Diabetes; Mesenchymal Stem Cells
MeSH terms: Diabetes Mellitus; Diabetes Mellitus, Type 2
Study type: Interventional
Phase: Phase 2

Summary: 
      Umbilical cord mesenchymal stem cells indicate the therapeutic effects and safety on type 2
      diabetes by characteristics of secretion and immune Immunomodulation.
    

Detailed description: 
      Umbilical cord mesenchymal stem cells can improve insulin resistance of the target tissues,
      reduce the islet progressive damage, ease or regenerate of the islet beta cells and improve
      hyperglycemic state of diabetes by secreting a variety of cytokines. It can induce damaged
      alpha cells differentiate into beta cells in the islet transformation to realize the islet
      beta cells in situ regeneration by improving microenvironment of islet beta cells. Umbilical
      cord mesenchymal stem cells also have immunosuppressive effect, it can promote islet cell
      repair and regeneration by the inhibition of T cell mediated immune response to beta cells.
    

Intervention name(s): Umbilical cord mesenchymal stem cells; Controlled suspension liquid
Intervention type(s): Biological; Biological
Intervention description(s): Infusion treatment; Infusion treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Intervention model description: UC-MSCs (1.5×106/kg) or the same volume of placebo (suspension liquid without UC-MSCs)
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Mechanical Ventilation Controlled by the Electrical Activity of the Patient's Diaphragm - Effects on Cardiac Performance
Condition: Respiratory Failure; Cardiac Failure
MeSH terms: Respiratory Insufficiency; Heart Failure
Study type: Interventional
Phase: Phase 1

Summary: 
      Neurally adjusted ventilatory assist (NAVA) is a new concept of mechanical ventilation. NAVA
      delivers assist to spontaneous breathing based on the detection of the electrical activity of
      the diaphragm. We study the effect of NAVA on cardiac performance in critically ill,
      mechanically ventilated patients.
    


Intervention name(s): Neurally adjusted ventilatory assist (NAVA) provided by a commercially available mechanical ventilator (Servo i, Maquet Critical Care, Solna, Sweden).
Intervention type(s): Device
Intervention description(s): Neurally adjusted ventilatory assist (NAVA) and pressure support ventilation (PSV)
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: respiratory insufficiency; respiration; ventilators; diaphragm; electromyography; mechanical ventilation
Training Cognitive Control Processes in Older Adults
Condition: Neurologic Manifestations; Neurobehavioral Manifestations
MeSH terms: Neurologic Manifestations; Neurobehavioral Manifestations
Study type: Interventional

Summary: 
      Control processes are classes of brain activity that initiate, coordinate, synchronize, and
      regulate elemental cognitive functions for the conduct of goal-directed behavior. The
      proposed research investigates whether exposure to a computer-based training protocol
      designed to enhance cognitive control processes will improve cognitive performance in healthy
      older adults.
    

Detailed description: 
      The proposed research investigates whether exposure to a computer-based training protocol
      designed to enhance cognitive control processes will improve cognitive performance in healthy
      older adults. Cognitively normal adults aged 60-75 will be randomized into three experimental
      groups: 1) Video game play with training strategy; 2) Video game play without training
      strategy (Active Control); 3) Minimal contact (Passive Control). Subjects in Groups 1 and 2
      will be instructed to play the complex, high-demand video game, Space Fortress, for 36
      one-hour sessions over 12 weeks. Subjects in Group 3 will receive all assessments but will
      not play the computer game.
    

Intervention name(s): Video game based training
Intervention type(s): Behavioral
Intervention description(s): 36 one-hour sessions over 12 weeks
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Participant)
Keywords: cognition; cognition disorders; executive function; cognitive control; attentional control; biomedical enhancement; cognitive enhancement; computerized; computer-based; video game
Effect of Community Social Mobilization for the Prevention of HIV in Young South African Women
Condition: Gender Relations
Study type: Interventional

Summary: 
      The overall purpose is to assess whether a community social mobilization (CSM) program
      focused on young men ages 18-35 years of age changes gender norms in the community. The
      secondary purpose is to determine if there is a combined effect of CSM and HPTN 068
      (Conditional Cash Transfers) on HIV and HSV-2 incidence. The goal of the mobilization
      activities is to engage young men around the issues of gender norms, intimate partner
      violence and HIV risk and to encourage them to take action to protect young women and reduce
      HIV risk in their communities.
    


Intervention name(s): Community Social Mobilization program
Intervention type(s): Behavioral
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary purpose: Prevention
Keywords: Community Mobilization; HIV; Intimate Partner Violence; Gender Norms
S0910 Epratuzumab, Cytarabine, and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Condition: Leukemia
MeSH terms: Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphoid
Study type: Interventional
Phase: Phase 2

Summary: 
      RATIONALE: Monoclonal antibodies, such as epratuzumab, can block cancer growth in different
      ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and
      help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such
      as cytarabine and clofarabine, work in different ways to stop the growth of cancer cells,
      either by killing the cells or by stopping them from dividing. Giving epratuzumab together
      with cytarabine and clofarabine may kill more cancer cells.

      PURPOSE: This phase II trial is studying the side effects and how well giving epratuzumab
      together with cytarabine and clofarabine works in treating patients with relapsed or
      refractory acute lymphoblastic leukemia.
    

Detailed description: 
      OBJECTIVES:

        -  To test whether the complete remission (CR) rate (CR and incomplete CR) in adult
           patients with relapsed or refractory precursor B-cell acute lymphoblastic leukemia is
           sufficiently high after treatment with cytarabine, clofarabine, and epratuzumab to
           warrant further investigation.

        -  To estimate the frequency and severity of toxicities associated with the dosing schedule
           of cytarabine, clofarabine, and epratuzumab used in this study.

        -  To investigate, preliminarily, the effect of laboratory correlates (minimal
           post-treatment residual disease) and cytogenetic factors on prognosis in this patient
           population. (Not reported here due to limited MRD data)

      OUTLINE: This is a multicenter study.

      Patients receive cytarabine IV over 2 hours on days 1-5, clofarabine IV over 1 hour on days
      2-6, and epratuzumab IV over at least 1 hour on days 7, 14, 21, and 28 in the absence of
      disease progression or unacceptable toxicity*.

      NOTE: * Prophylactic intrathecal methotrexate is required for patients < 22 years of age, and
      is recommended (but not required) for patients ≥ 22 years of age.

      Blood samples, bone marrow samples, and/or tumor tissue samples may be collected for further
      laboratory analysis.

      Patients are followed up every 3 months for 2 years, then annually for 3 years (until 5 years
      after registration).
    

Intervention name(s): epratuzumab; clofarabine; cytarabine; laboratory biomarker analysis
Intervention type(s): Biological; Drug; Drug; Other
Intervention MeSH terms: Cytarabine; Clofarabine; Epratuzumab
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: B-cell adult acute lymphoblastic leukemia; L1 adult acute lymphoblastic leukemia; L2 adult acute lymphoblastic leukemia; recurrent adult acute lymphoblastic leukemia
A Clinical Trial to Assess the Safety of a Measles Vaccine (Dry Powder) Administered by Two Different Devices
Condition: Prophylaxis for the Measles Infection
MeSH terms: Measles
Study type: Interventional
Phase: Phase 1

Summary: 
      This is a phase I, open-label, randomized study in healthy adults. Eligible subjects will be
      given single dose of either Dry Powdered Measles Vaccine (PMV) by Puffhaler® device, Dry PMV
      by SoloventTM device or licensed measles vaccine by subcutaneous route (SMV). Subjects will
      be followed for 180 days for safety.
    

Detailed description: 
      This is a phase I, open-label, randomized study in healthy adults. Eligible subjects will be
      given single dose of either Dry Powdered Measles Vaccine (PMV) by Puffhaler® device, Dry PMV
      by SoloventTM device or licensed measles vaccine by subcutaneous route (SMV). Solicited
      reactions will be assessed for first 14 days after vaccination and unsolicited adverse events
      will be assessed till 84 days after vaccination. Subjects will be followed for 180 days for
      any SAEs.
    

Intervention name(s): PMV via Puffhaler® device; PMV via SoloventTM device; Licensed Subcutaneous Measles Vaccine
Intervention type(s): Biological; Biological; Biological
Intervention description(s): The vaccine will be administered via a Puffhaler® device. A single dose of 10 mg of PMV (dry powder measles vaccine) will be used.; The vaccine will be administered via SoloventTM device. A single dose of 10 mg of PMV (dry powder measles vaccine) will be used.; This is a licensed formulation containing the live attenuated Edmonston Zagreb virus. A single dose of 0.5 ml will be given subcutaneously.
Other intervention name(s): SMV
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Prevention
Interferon Responses in Eczema Herpeticum
Condition: Atopic Dermatitis; Eczema Herpeticum; Herpes Simplex Infections; Eczema Vaccinatum
MeSH terms: Herpes Simplex; Kaposi Varicelliform Eruption; Dermatitis, Atopic; Dermatitis; Eczema
Study type: Observational

Summary: 
      Atopic dermatitis (AD) is a chronic skin disorder characterized by recurrent viral skin
      infections. A small subset of patients with AD suffer from disseminated viral infections,
      e.g., eczema herpeticum (ADEH+), after herpes simplex infection (HSV) or eczema vaccinatum
      (EV) after smallpox vaccination. Interferon gamma (IFNγ) plays a critical role in the innate
      and acquired immune responses by activating macrophages, enhancing natural killer cell
      activation, and promoting T cell differentiation, as well as regulating B cell isotype
      switching to immunoglobulin (Ig) G2a. Recent studies have demonstrated that IFNγ generation
      was significantly decreased after stimulation with HSV ex vivo. The purpose of this study is
      to determine if deficient IFNγ induction leads to susceptibility to HSV infection in ADEH+
      patients.
    

Detailed description: 
      The investigators hypothesize that defective IFNγ responses in peripheral blood mononuclear
      cells (PBMCs) from ADEH+ patients results from aberrant pattern recognition receptors (PRR)
      signaling in antigen-presenting cells (APCs) resulting in low level production of IL-12, an
      essential cytokine for IFNγ generation. This study will compare results from 40 ADEH+, 40
      ADEH-, and 40 non-atopic participants.

      Study procedures will typically be completed in one visit; however, participants may be asked
      to return for additional unscheduled visit(s) occurring as frequently as every 3 months for
      the duration of the study to provide an additional blood sample for further characterization
      of immune mechanisms leading to reduced IFNγ responses in ADEH+.
    

Observational model: Other
Time perspective: Prospective
Sampling method: Non-Probability Sample
Study population: 
        40 ADEH+, 40 ADEH-, and 40 non-atopic controls ages 6 to 65 years. Initially, 20 ADEH- and
        20 non-atopic control participants will be gender- and age-matched (plus or minus 10 years)
        to 20 ADEH+ participants. Afterwards, additional participants will be enrolled such that
        the gender ratio and the age distribution of the ADEH+ participants will be similar to that
        of the ADEH- and non-atopic control participants
      
Biospecimen description: 
      Blood samples, RNA, serum, protein and cells will be retained.
    
Keywords: Atopic Dermatitis; Eczema herpeticum; Interferon gamma; IFNγ
BodyGuardian Respiration and Activity Validation Testing
Condition: Healthy
Study type: Observational

Summary: 
      This project will compare BodyGuardian (BG) device measurements of breathing and activity
      levels to the gold standard measurement techniques of gas exchange using a mouthpiece
      connected to flow and gas analyzers measures for breathing and metabolic rate (indirect
      calorimetry) for activity, We are hopeful these comparisons will help us improve upon the
      measurements being made in the current version of the BG device.
    

Detailed description: 
      BodyGuardian remote monitoring system is an FDA 510 cleared device used to perform remote
      monitoring of cardiac patients. BodyGuardian (BG) is a novel remote care platform. It
      incorporates an adhesive strip sensor with in-built electrodes attached to a rechargeable
      module that can determine an ECG signal and bio impedance. The module also has a 3-way
      accelerometer. ECG, physical activity and respiration can be assessed using these sensors.
      Although ECG data is reliable, there are doubts regarding the clinical meaning and validity
      of the activity and respiration data.

      The BG reports respiration rate and activity level (on a scale of 0 to 100). This data is
      being used as input into other clinical algorithms including onboard ECG arrhythmia detection
      as well as clinical care algorithms for heart failure decompensation prediction.

      Respiration data is not uniformly reported and there is still doubt regarding its validity.
      BG breathing measurements will be compared to gold standard measurement techniques of gas
      exchange using a mouthpiece connected to flow and gas analyzer. Activity data is reported but
      the investigators do not know how the value translates into clinically used objective
      parameters of activity e.g. METS. BG activity measurements will be compared to the gold
      standard activity measurements using metabolic rate (indirect calorimetry)
    

Intervention name(s): BodyGuardian
Intervention type(s): Device
Intervention description(s): BodyGuardian (BG) device will be worn by all subjects to determine accuracy of respiration and activity levels monitored by BG
Observational model: Cohort
Time perspective: Prospective
Sampling method: Non-Probability Sample
Study population: 
        Healthy volunteers and Heart Failure patients
Single-centre, Randomised, Double-blind, Placebo-controlled, Four-way Crossover Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Single Doses of CM3.1-AC100 in Patients With Type 2 Diabetes
Condition: Type II Diabetes Mellitus
MeSH terms: Diabetes Mellitus; Diabetes Mellitus, Type 2
Study type: Interventional
Phase: Phase 1

Summary: 
      The primary objective of this study is to assess the safety and tolerability of the
      Glucagon-like peptide-1 (GLP-1) peptide analogue CM3.1-AC100 after single subcutaneous (sc)
      doses in patients with T2DM.
    


Intervention name(s): CM3.1-AC100
Intervention type(s): Drug
Intervention description(s): SAD study with single ascending subcutaneous doses
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary purpose: Basic Science
The Proactive Support of Labor Study
Condition: Obstetric Labor Complications
MeSH terms: Obstetric Labor Complications
Study type: Interventional

Summary: 
      The duration of labor is decisive for maternal and fetal health. Poor progression often
      results in tired mothers, bad experience, delivery complications and a demand for cesarean
      section in next pregnancy. Proactive support of labor is a method originally from the
      Netherlands.

      The main idea is to define start of active labor earlier than the traditional "3-4 cm opening
      of the cervix and regular contractions" to be cervix < 0.5 cm in length, and 1 cm opening and
      painful contractions. From this point, it is expected to be a progress of 1cm/hour opening of
      cervix. If not, progress is supported by amniotomy or stimulation of contractions.

      This method is embraced by several clinics with great enthusiasm. However, there are no
      randomized controlled trials to prove that this method is better than others.
    


Intervention name(s): Proactive support of labor; support of labor as usual
Intervention type(s): Behavioral; Behavioral
Intervention description(s): In case of delayed labor, active labor is defined at an earlier stage; labor support is given with 1 cm opening of the cervix and painful contractions. Labor support interventions are started then.; In case of delayed labor, active labor start is defined as usual at 3-4 cm opening of the cervix and regular contractions. Labor support interventions are started then.
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Supportive Care
Keywords: Delivery, Obstetric; Uterine Contraction; Cervix Uteri
The Effect of Patient Position on Postdural Puncture Headache
Condition: Pregnancy; Headache
MeSH terms: Headache
Study type: Observational

Summary: 
      We aimed to investigate the association between the position in which spinal anesthesia was
      performed and postdural puncture headache occurrence.
    

Detailed description: 
      Records of patients who underwent caesarean section between January, 2013 and November, 2013
      with spinal anesthesia will be retrospectively examined. Demographic data of patients,
      comorbid diseases, position of patient while performing spinal anesthesia, the number of
      spinal puncture attempts will be recorded.
    

Intervention name(s): lateral; sitting
Intervention type(s): Other; Other
Intervention description(s): spinal anesthesia performed during lateral position; spinal anesthesia performed during sitting position
Time perspective: Retrospective
Sampling method: Probability Sample
Study population: 
        Patients records form patients who experienced headache after caesarean section with spinal
        anesthesia were retrospectively evaluated